CANAQUEST Announces Award of European Cannabinoid Patent

About this update from Canaquest Medical Corporation

EU Patent #19846183.2 - A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL ("THC") FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTSWe believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability.TORONTO, ON / ACCESSWIRE / September 19, 2023 / CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") Formulation for the reduction of cannabis-induced negative neuropsychiatric side-effects.The formulated product is branded as Mentabinol®, which addresses various psychiatric disorders. Acute THC consumption can trigger paranoid thoughts in vulnerable individuals.Mentabinol® - Formulation utilizing pharmaceutical-grade botanical extract, L-theanine, and THC molecules extracted from cannabis.The Scientific Difference - based on pre-clinical trial results at Western UniversityTHC vs Mentabinol®For many users, THC causes:Memory impairment and possible long-term cognitive side effects,Depression-like and schizophrenia-related symptoms,Anxiety and hyperactive activity,Schizophrenia due to gene vulnerability.Application of Mentabinol® has demonstrated in pre-clinical trials:Reversal of depression-like and schizophrenia-related symptom effects,Blockage of memory impairment, hyperactive activity, and gene vulnerability.The discovery was made by a research team led by Dr. Steven Laviolette, a professor, and neuroscientist at Western University with decades of experience in the fields of mental health and cannabinoids.Western University's Dr. Steven Laviolette said, "What we found was that by administering L-theanine along with the THC-based formulation, we were able to block several side effects of THC exposure, including changes to schizophrenia-related neurochemical pathways, and abnormalities in behaviors - including cogniti...

View stock analysis, news, and events for Canaquest Medical Corporation